M Hallett

National Eye Institute, Maryland, United States

Are you M Hallett?

Claim your profile

Publications (354)1992.97 Total impact

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: These guidelines provide an up-date of previous IFCN report on "Non-invasive electrical and magnetic stimulation of the brain, spinal cord and roots: basic principles and procedures for routine clinical application" (Rossini et al., 1994). A new Committee, composed of international experts, some of whom were in the panel of the 1994 "Report", was selected to produce a current state-of-the-art review of non-invasive stimulation both for clinical application and research in neuroscience. Since 1994, the international scientific community has seen a rapid increase in non-invasive brain stimulation in studying cognition, brain-behavior relationship and pathophysiology of various neurologic and psychiatric disorders. New paradigms of stimulation and new techniques have been developed. Furthermore, a large number of studies and clinical trials have demonstrated potential therapeutic applications of non-invasive brain stimulation, especially for TMS. Recent guidelines can be found in the literature covering specific aspects of non-invasive brain stimulation, such as safety (Rossi et al., 2009), methodology (Groppa et al., 2012) and therapeutic applications (Lefaucheur et al., 2014). This up-dated review covers theoretical, physiological and practical aspects of non-invasive stimulation of brain, spinal cord, nerve roots and peripheral nerves in the light of more updated knowledge, and include some recent extensions and developments. Copyright © 2015 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.
    Clinical Neurophysiology 02/2015; DOI:10.1016/j.clinph.2015.02.001 · 2.98 Impact Factor
  • P. Zhuang, M. Hallett, X. Li, Y. Zhang, J. Li, Y. Li
    Clinical Neurophysiology 06/2014; 125:S127-S128. DOI:10.1016/S1388-2457(14)50416-6 · 2.98 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To study the temporal dynamics of tissue impedance after deep brain stimulation (DBS). DBS therapy commonly employs a constant voltage approach, and current delivery to the tissue is a function of electrode-tissue impedance. It is presumed that impedance fluctuates early postimplantation, with implications for variations in current delivery and therapeutic efficacy. We hypothesised that the largest variation will be recorded early after surgery, followed by stabilisation. Review of impedance checks of implanted DBS systems at standard parameters during the first five months postimplantation. All measurement time points were binned into 1-week periods, and we used repeated measures analysis of variance with Tukey pairwise multiple comparisons correction. The analysis was repeated after normalising impedance values for each subject to that patient's baseline value. There was an initial (non-significant) drop in impedance at week 1, followed by significant increase at week 3 (p=0.0002). There were no further significant differences in impedance values at subsequent time points. Analysis of normalised data showed a significant difference between the initial measurement in postoperative week 1 (normalised value 1) and week 3 (normalised value 1.73, p<0.0001), with no further difference among the subsequent weekly points during the 5-month follow-up. No significant hourly variations were found at any time points. We found major changes in impedance within the first month postimplantation, with no further variation. This is an important confirmation in patients of this temporal dynamics of the impedance of implanted DBS hardware, with potential therapeutic implications.
    Journal of neurology, neurosurgery, and psychiatry 11/2013; 85(7). DOI:10.1136/jnnp-2013-306066 · 5.58 Impact Factor
  • K. E. Alter, M. Hallett, B. Karp, C. Lungu
    Toxicon 06/2013; 68:68–69. DOI:10.1016/j.toxicon.2012.07.039 · 2.58 Impact Factor
  • Source
    Toxicon 01/2013; · 2.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND AND PURPOSE: Injectable botulinum neurotoxin (BoNT) is the principal effective treatment for blepharospasm (BSP). This trial explores the safety and efficacy of topical acetyl hexapeptide-8 (AH8), a competitive SNAP25 inhibitor, as a potential new therapy in BSP. METHODS: Double-blind, placebo-controlled, randomized trial of daily topical application of AH8 in 24 patients with BSP. The primary outcome was time to return to baseline Jankovic Rating Scale (JBRS) after a BoNT injection simultaneously with the initiation of AH8. Patients displaying a strictly regular pattern of response to 3-monthly injections of BoNT were included. RESULTS: There were no significant adverse events. There was a trend for longer time until return to baseline JBRS after injection in the active group compared to placebo (3.7 months vs. 3.0 months), and for better scores in the active group. One-third (4/12) of the patients in the active group had a considerable extension of symptom control after BoNT (range: 3.3-7.1 months). CONCLUSIONS: Topical AH8 is safe and promising for extending the duration of action of BoNT therapy for BSP.
    European Journal of Neurology 11/2012; 20(3). DOI:10.1111/ene.12009 · 3.85 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Subthalamic nucleus deep brain stimulation (STN DBS) is an effective surgical treatment for Parkinson's disease (PD). Recent studies demonstrated that pathological oscillations are seen largely within the dorsolateral portion of the STN, which is the same location that predicts optimal therapeutic benefit with DBS; however, the precise nature of the relationship between these two phenomena remains unclear. The purpose of this study was to explore localization of oscillatory activity in relation to the optimal contacts of DBS which results in the best motor improvement. We studied 23 PD patients who underwent electrode implantation into the STN for motor symptoms. Microelectrode recordings were taken from the STN during surgery and neuronal activity was analyzed offline. Spectral characteristics were calculated. Clinical outcomes were evaluated pre- and post-STN DBS implantation using the Unified Parkinson's Disease Rating Scale (UPDRS III). The position of optimal electrode contacts was assessed by postoperative magnetic resonance imaging (MRI) and was compared to the location of oscillatory activity within the STN as well as its dorsal margin (where STN neuronal activity was first detected). Of the total 188 neurons obtained, 51 (27.1%) neurons showed significant oscillatory activity. Of those, 47 (92.2%) were localized in the dorsal portion of the STN. Furthermore, there was no significant difference between the averaged coordinates of the position of 40 optimal contacts and the coordinates of the dorsal margin of the STN. The data indicate that the positions of the best contacts correlate with the locations of the oscillatory neurons supporting the prediction that stimulation of the dorsolateral oscillatory region leads to an effective clinical outcome for STN DBS surgery.
    Parkinsonism & Related Disorders 09/2012; 19(1). DOI:10.1016/j.parkreldis.2012.08.005 · 4.13 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Deep brain stimulation (DBS) is a highly promising therapy for Parkinson's disease (PD). However, most patients do not get full therapeutic benefit from DBS, due to its critical dependence on electrode location in the Subthalamic Nucleus (STN). For this reason, we believe that the development of a novel surgical tool for DBS placement, i.e., an automated intraoperative closed-loop DBS localization system, is essential. In this paper, we analyze single unit spiking activity of 120 neurons in different STN locations collected from 4 PD patients. Specifically, for each neuron, we estimate a point process model (PPM) of the spiking activity for different depths within the STN by which we are able to detect pathological bursting and oscillations. Our results suggest that these signatures are more prominent in the dorsolateral part of the STN. Therefore, accurately placing the DBS electrode in this target may result in maximal therapeutic benefit with less power effort required by DBS. Furthermore, PPMs might be an effective tool for modeling of the STN neuronal activities as a function of location within the STN, which may pave the way towards developing a closed-loop navigation tool for optimal DBS electrode placement.
    Conference proceedings: ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Conference 08/2012; 2012:2539-42. DOI:10.1109/EMBC.2012.6346481
  • Neurology 04/2012; 78(Meeting Abstracts 1):P03.124-P03.124. DOI:10.1212/WNL.78.1_MeetingAbstracts.P03.124 · 8.30 Impact Factor
  • Neurology 04/2012; 78(Meeting Abstracts 1):P04.026-P04.026. DOI:10.1212/WNL.78.1_MeetingAbstracts.P04.026 · 8.30 Impact Factor
  • Neurology 04/2012; 78(Meeting Abstracts 1):P01.189-P01.189. DOI:10.1212/WNL.78.1_MeetingAbstracts.P01.189 · 8.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Deep brain stimulation (DBS) is a highly promising therapy for Parkinson's disease (PD). However, most patients do not get full therapeutic benefit from DBS yet, due to its critical dependence on electrode location. For this reason, we believe that the investigation of a neural modeling, estimation and control framework for the STN is an interesting research problem. This would pave the way for the development of a novel surgical tool for the DBS placement standardization, i.e., an automated intraoperative closed-loop DBS localization system. A fundamental problem to be solved for the realization of a such framework is the neurophysiologic characterization of the STN activity. Indeed, this would allow to understand if the modeling of the sweet spot is feasible. In this paper an effort towards the modeling of the neuronal activity near the stimulation target is made: first we analyze single unit spiking activity of 120 STN neurons collected from four PD patients at different distances from the sweet spot and, for each neuron, we estimate a point process model (PPM). Then, we see that PPMs capture the stochastic effects of the distance from the sweet spot on the STN spiking activity, and characterize the impact of local neuronal networks on the single neurons. Our results suggest that PPMs might be an effective tool for modeling of the STN neuronal activities accounting for the depth within it.
    Control Applications (CCA), 2012 IEEE International Conference on; 01/2012
  • P. Zhuang, M. Hallett, Y. Zhang, J. Li, Y. Li
    Parkinsonism & Related Disorders 01/2012; 18:S66-S67. DOI:10.1016/S1353-8020(11)70337-6 · 4.13 Impact Factor
  • M. Hallett, W.J. Weiner, K. Kompoliti
    Parkinsonism & Related Disorders 01/2012; 18:S88. DOI:10.1016/S1353-8020(11)70424-2 · 4.13 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Valid assessment of apraxia in usually non-apraxic Parkinson's disease helps to delineate atypical parkinsonism frequently associated with apraxia. Furthermore, in a subgroup of late Parkinson's disease apraxia, typically the ideomotor subtype, may gradually superimpose onto parkinsonian motor symptoms contributing to defective manual skill. Here we evaluate the utility of a brief, standardized test, the apraxia screen of TULIA (AST). Seventy five Parkinson's disease patients were tested with the AST. Parkinsonian motor deficits were measured using Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III and difficulties in activities of daily living (ADL) by modified MDS-UPDRS part II (eating, dressing, personal hygiene, and writing). No association was found between the AST and MDS-UPDRS part III, indicating that AST discriminates well (discriminative validity) between apraxia and parkinsonism. Furthermore, AST was associated with ADL and Hoehn & Yahr stage (convergent validity). AST is a short and valid test to rule out or detect apraxia in Parkinson's disease.
    Parkinsonism & Related Disorders 12/2011; 18(4):348-50. DOI:10.1016/j.parkreldis.2011.11.023 · 4.13 Impact Factor
  • Clinical Neurophysiology 06/2011; 122. DOI:10.1016/S1388-2457(11)60538-5 · 2.98 Impact Factor
  • Source
    Clinical Neurophysiology 06/2011; 122. DOI:10.1016/S1388-2457(11)60718-9 · 2.98 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There is still controversy in the literature whether a single episode of mild traumatic brain injury (mTBI) results in short- and/or long-term functional and structural deficits in the concussed brain. With the inability of traditional brain imaging techniques to properly assess the severity of brain damage induced by a concussive blow, there is hope that more advanced applications such as resting state functional magnetic resonance imaging (rsFMRI) will be more specific in accurately diagnosing mTBI. In this rsFMRI study, we examined 17 subjects 10±2 days post-sports-related mTBI and 17 age-matched normal volunteers (NVs) to investigate the possibility that the integrity of the resting state brain network is disrupted following a single concussive blow. We hypothesized that advanced brain imaging techniques may reveal subtle alterations of functional brain connections in asymptomatic mTBI subjects. There are several findings of interest. All mTBI subjects were asymptomatic based upon clinical evaluation and neuropsychological (NP) assessments prior to the MRI session. The mTBI subjects revealed a disrupted functional network both at rest and in response to the YMCA physical stress test. Specifically, interhemispheric connectivity was significantly reduced in the primary visual cortex, hippocampal and dorsolateral prefrontal cortex networks (p<0.05). The YMCA physical stress induced nonspecific and similar changes in brain network connectivity patterns in both the mTBI and NV groups. These major findings are discussed in relation to underlying mechanisms, clinical assessment of mTBI, and current debate regarding functional brain connectivity in a clinical population. Overall, our major findings clearly indicate that functional brain alterations in the acute phase of injury are overlooked when conventional clinical and neuropsychological examinations are used.
    NeuroImage 04/2011; 55(4):1716-27. DOI:10.1016/j.neuroimage.2011.01.024 · 6.13 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To characterize patients with benign essential blepharospasm (BEB) by diagnosis, environmental risk factors, and family history. Two hundred and forty patients with BEB were evaluated through a clinical examination and questionnaire. The questionnaire reviewed personal medical history, demographic factors, risk factors for the development of blepharospasm and family history of dystonia and other neurological conditions. Benign essential blepharospasm was more commonly found in women (2.8:1) and 93% of the patients were Caucasian. Fifty percent had pure BEB, 31% had BEB/Meige's syndrome, and 4% had BEB and eyelid opening apraxia (+/- Meige's syndrome). A minority of patients reported preceding photophobia (25%) or other eye conditions (22%). The majority were non-smokers, had no exposure to anti-emetic or antipsychotic agents, had a normal birth history, and had no history of head trauma. Seventy-two percent did report a stressful event immediately prior to the development of symptoms. Treatments reported included botulinum toxin (BoNT), oral medications, surgical procedures, and acupuncture. Thirty-two percent of patients reported a family history of focal dystonia, and BEB was the most commonly reported. This study confirms previous reports of usual age, sex, caffeine and tobacco use, and family history in patients with blepharospasm. New findings include a report on occupation, lower reports of preceding eye conditions and photophobia, and higher reported stressful events. Further, this study shows a change in treatment with an increase in BoNT use and decrease in surgical procedures.
    European Journal of Neurology 03/2011; 18(3):382-6. DOI:10.1111/j.1468-1331.2010.03161.x · 3.85 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the safety and efficacy of intermittent theta-burst stimulation (iTBS) in the treatment of motor symptoms in Parkinson disease (PD). Progression of PD is characterized by the emergence of motor deficits, which eventually respond less to dopaminergic therapy and pose a therapeutic challenge. Repetitive transcranial magnetic stimulation (rTMS) has shown promising results in improving gait, a major cause of disability, and may provide a therapeutic alternative. iTBS is a novel type of rTMS that may be more efficacious than conventional rTMS. In this randomized, double-blind, sham-controlled study, we investigated safety and efficacy of iTBS of the motor and dorsolateral prefrontal cortices in 8 sessions over 2 weeks (evidence Class I). Assessment of safety and clinical efficacy over a 1-month period included timed tests of gait and bradykinesia, Unified Parkinson's Disease Rating Scale (UPDRS), and additional clinical, neuropsychological, and neurophysiologic measures. We investigated 26 patients with mild to moderate PD: 13 received iTBS and 13 sham stimulation. We found beneficial effects of iTBS on mood, but no improvement of gait, bradykinesia, UPDRS, and other measures. EEG/EMG monitoring recorded no pathologic increase of cortical excitability or epileptic activity. Few reported discomfort or pain and one experienced tinnitus during real stimulation. iTBS of the motor and prefrontal cortices appears safe and improves mood, but failed to improve motor performance and functional status in PD. Classification of evidence: This study provides Class I evidence that iTBS was not effective for gait, upper extremity bradykinesia, or other motor symptoms in PD.
    Neurology 02/2011; 76(7):601-9. DOI:10.1212/WNL.0b013e31820ce6bb · 8.30 Impact Factor

Publication Stats

27k Citations
1,992.97 Total Impact Points


  • 1997–2011
    • National Eye Institute
      Maryland, United States
  • 1988–2011
    • National Institutes of Health
      • • Division of Intramural Research (Dental Research)
      • • Division of Intramural Research
      • • Rehabilitation Medicine Department
      Maryland, United States
  • 1995–2010
    • Northern Inyo Hospital
      BIH, California, United States
    • U.S. Food and Drug Administration
      • Center for Food Safety and Applied Nutrition
      Washington, D. C., DC, United States
  • 2007
    • National Institute of Mental Health (NIMH)
      • Molecular Imaging Branch
      Maryland, United States
  • 2006
    • Ospedale Pediatrico Bambino Gesù
      Roma, Latium, Italy
  • 2001
    • Goethe-Universität Frankfurt am Main
      Frankfurt, Hesse, Germany
  • 1996–2001
    • University of Adelaide
      • School of Medicine
      Tarndarnya, South Australia, Australia
  • 2000
    • Georgetown University
      • Institute for Cognitive and Computational Sciences
      Washington, Washington, D.C., United States
    • American Academy of Neurology
      Saint Paul, Minnesota, United States
  • 1998
    • Fondazione Salvatore Maugeri IRCCS
      Ticinum, Lombardy, Italy
    • Sapienza University of Rome
      • Department of Anatomical, Histological, Forensic Medicine and Orthopedic Science
      Roma, Latium, Italy
  • 1994
    • University of Valencia
      Valenza, Valencia, Spain
    • Johns Hopkins University
      Baltimore, Maryland, United States
  • 1990
    • Second University of Naples
      Caserta, Campania, Italy
    • Howard University
      • Department of Physics & Astronomy
      Washington, WV, United States
  • 1985
    • Harvard Medical School
      • Department of Neurology
      Boston, Massachusetts, United States